Targets › DNMT3B
2 programs from 2 companies in 3 trials: 2 Phase 1, 1 Phase 2; Oncology; next expected readout Dec 2026.
DNA (cytosine-5)-methyltransferase that mediates genome-wide de novo methylation and which is essential for the establishment of DNA methylation patterns during development. Modifies DNA at CpG sites with selectivity for residues flanking the target CpG site at positions -1 and +1, and strong preference for a guanine (G) immediately following the CpG sites. (UniProt, Q9UBC3)
Open in Phaseline: the race on DNMT3B, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Guadecitabine DNA methyltransferase (DNMT) inhibitor | DNMT1, DNMT3A, DNMT3B | Phase 2 | Locally Advanced Unresectable Primary Central Chondrosarcoma | Jan 2027 |
| University of Southern California | Guadecitabine DNMT inhibitor | DNMT1, DNMT3A, DNMT3B | Phase 1 | Extrahepatic Bile Duct Adenocarcinoma, Biliary Type; Chronic Myelomonocytic Leukemia | Dec 2026 |
Extrahepatic Bile Duct Adenocarcinoma, Biliary Type (1) Chronic Myelomonocytic Leukemia (1) Locally Advanced Unresectable Primary Central Chondrosarcoma (1)
mixed (1), small molecule (1)
University of Southern California (1) National Cancer Institute (NCI) (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.